Daniel J. Herr

Daniel J. Herr

Auto-generated profile, based on publicly available information

Daniel J. Herr

Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
SASverre E. Aune
Sverre E. Aune
DHDaniel J. Herr
Daniel J. Herr
SMSanthosh K. Mani
Santhosh K. Mani
DMDonald R. Menick
Donald R. Menick

27 July 2015 in Journal of Visualized Experiments
Verified
Journal Article
Closed access
PDF file
DHDaniel J. Herr
Daniel J. Herr
SASverre E. Aune
Sverre E. Aune
DMDonald R. Menick
Donald R. Menick
The biochemical events surrounding ischemia reperfusion injury in the acute setting are of great importance to furthering novel treatment options for myocardial infarction and cardiac complications of thoracic surgery. The ability of certain drugs to precondition the myocardium against ischemia reperfusion injury has led to multiple clinical trials, with little success. The isolated heart model allows acute observation of the functional effects of ischemia reperfusion injury in real time, including the effects of various pharmacological interventions administered at any time-point before or within the ischemia-reperfusion injury window. Since brief periods of ischemia can precondition the heart against ischemic injury, in situ aortic cannulation is performed to allow for functional assessment of non-preconditioned myocardium. A saline filled balloon is placed into the left ventricle to allow for real-time measurement of pressure generation. Ischemic injury is simulated by the cessation of perfusion buffer flow, followed by reperfusion. The duration of both ischemia and reperfusion can be modulated to examine biochemical events at any given time-point. Although the Langendorff isolated heart model does not allow for the consideration of systemic events affecting ischemia and reperfusion, it is an excellent model for the examination of acute functional and biochemical events within the window of ischemia reperfusion injury as well as the effect of pharmacological intervention on cardiac pre- and postconditioning. The goal of this protocol is to demonstrate how to perform in situ aortic cannulation and heart excision followed by ischemia/reperfusion injury in the Langendorff model.

30 June 2015 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
SASverre E. Aune
Sverre E. Aune
DHDaniel J. Herr
Daniel J. Herr
CKCraig J. Kutz
Craig J. Kutz
DMDonald R. Menick
Donald R. Menick
Ischemia-reperfusion (IR) injury comprises a significant portion of morbidity and mortality from heart and brain diseases worldwide. This enduring clinical problem has inspired myriad reports in the scientific literature of experimental interventions seeking to elucidate the pathology of IR injury. Elective cardiac surgery presents perhaps the most viable scenario for protecting the heart and brain from IR injury due to the opportunity to condition the organs prior to insult. The physiological parameters for the preconditioning of vital organs prior to insult through mechanical and pharmacological maneuvers have been heavily examined. These investigations have revealed new insights into how preconditioning alters cellular responses to IR injury. However, the promise of preconditioning remains unfulfilled at the clinical level, and research seeking to implicate cell signals essential to this protection continues. Recent discoveries in molecular biology have revealed that gene expression can be controlled through posttranslational modifications, without altering the chemical structure of the genetic code. In this scenario, gene expression is repressed by enzymes that cause chromatin compaction through catalytic removal of acetyl moieties from lysine residues on histones. These enzymes, called histone deacetylases (HDACs), can be inhibited pharmacologically, leading to the de-repression of protective genes. The discovery that HDACs can also alter the function of non-histone proteins through posttranslational deacetylation has expanded the potential impact of HDAC inhibitors for the treatment of human disease. HDAC inhibitors have been applied in a very small number of experimental models of IR. However, the scientific literature contains an increasing number of reports demonstrating that HDACs converge on preconditioning signals in the cell. This review will describe the influence of HDACs on major preconditioning signaling pathways in the heart and brain.

30 June 2023 in Cancer
Verified
Journal Article
Open access
DHDaniel J. Herr
Daniel J. Herr
DEDavid A. Elliott
David A. Elliott
GDGillian Duchesne
Gillian Duchesne
KSKristian D. Stensland
Kristian D. Stensland
MCMegan E. V. Caram
Megan E. V. Caram
TSTed A. Skolarus
Ted A. Skolarus
Purpose: Accurate information regarding real‐world outcomes after contemporary radiation therapy for localized prostate cancer is important for shared decision‐making. Clinically relevant end points at 10 years among men treated within a national health care delivery system were examined.Methods: National administrative, cancer registry, and electronic health record data were used for patients undergoing definitive radiation therapy with or without concurrent androgen deprivation therapy within the Veterans Health Administration from 2005 to 2015. National Death Index data were used through 2019 for overall and prostate cancer–specific survival and identified date of incident metastatic prostate cancer using a validated natural language processing algorithm. Metastasis‐free, prostate cancer–specific, and overall survival using Kaplan–Meier methods were estimated.Results: Among 41,735 men treated with definitive radiation therapy, the median age at diagnosis was 65 years and median follow‐up was 8.7 years. Most had intermediate (42%) and high‐risk (33%) disease, with 40% receiving androgen deprivation therapy as part of initial therapy. Unadjusted 10‐year metastasis‐free survival was 96%, 92%, and 80% for low‐, intermediate‐, and high‐risk disease. Similarly, unadjusted 10‐year prostate cancer–specific survival was 98%, 97%, and 90% for low‐, intermediate‐, and high‐risk disease. The unadjusted overall survival was lower across increasing disease risk categories at 77%, 71%, and 62% for low‐, intermediate‐, and high‐risk disease (p < .001).Conclusions: These data provide population‐based 10‐year benchmarks for clinically relevant end points, including metastasis‐free survival, among patients with localized prostate cancer undergoing radiation therapy using contemporary techniques. The survival rates for high‐risk disease in particular suggest that outcomes have recently improved.

28 May 2024 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
DHDaniel J. Herr
Daniel J. Herr
HYHuiying Yin
Huiying Yin
DBDerek Bergsma
Derek Bergsma
ADAleksandar F. Dragovic
Aleksandar F. Dragovic
MMMartha Matuszak
Martha Matuszak
PPPeter Paximadis
Peter Paximadis

20 July 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
DHDaniel J. Herr
Daniel J. Herr
CWChang Wang
Chang Wang
MMMishal Mendiratta-Lala
Mishal Mendiratta-Lala
MMMartha Matuszak
Martha Matuszak
CMCharles S. Mayo
Charles S. Mayo
KCKyle Cuneo
Kyle Cuneo
Purpose: We hypothesized that optimizing the utility of stereotactic body radiotherapy (SBRT) based on the individual patient's probability for tumor control and risk of liver injury would decrease toxicity without sacrificing local control in patients with impaired liver function or tumors not amenable to thermal ablation. Patients and Methods: Patients with Child-Pugh (CP) A to B7 liver function with aggregate tumor size >3.5 cm, or CP ≥ B8 with any size tumor were prospectively enrolled on an Institutional Review Board–approved phase II clinical trial to undergo SBRT with baseline and midtreatment dose optimization using a quantitative, individualized utility-based analysis. Primary endpoints were change in CP score of ≥2 points within 6 months and local control. Protocol-treated patients were compared with patients receiving conventional SBRT at another cancer center using overlap weighting. Results: A total of 56 patients with 80 treated tumors were analyzed with a median follow-up of 11.2 months. Two-year cumulative incidence of local progression was 6.4% [95% confidence interval (CI, 2.4–13.4)]. Twenty-one percent of patients experienced treatment-related toxicity within 6 months, which is similar to the rate for SBRT in patients with CP A liver function. An analysis using overlap weighting revealed similar local control [HR, 0.69; 95% CI (0.25–1.91); P = 0.48] and decreased toxicity [OR, 0.26; 95% CI (0.07–0.99); P = 0.048] compared with conventional SBRT. Conclusions: Treatment of individuals with impaired liver function or tumors not amenable to thermal ablation with a treatment paradigm designed to optimize utility may decrease treatment-related toxicity while maintaining tumor control.